Triple
T1169481
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | spinal muscular atrophy |
E24880
|
entity |
| Predicate | treatedBy |
P4714
|
FINISHED |
| Object | nusinersen |
E24879
|
NE FINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: nusinersen | Statement: [spinal muscular atrophy, treatedBy, nusinersen]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: nusinersen Context triple: [spinal muscular atrophy, treatedBy, nusinersen]
-
A.
Spinraza
chosen
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
B.
onasemnogene abeparvovec
Onasemnogene abeparvovec is a gene therapy medication that delivers a functional copy of the SMN1 gene to treat infants and young children with certain forms of spinal muscular atrophy.
-
C.
Aduhelm
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
D.
SMN2
SMN2 is a human gene that produces a backup form of survival motor neuron protein and is a key therapeutic target in spinal muscular atrophy.
-
E.
riluzole
Riluzole is a neuroprotective medication that modestly prolongs survival and slows disease progression in people with amyotrophic lateral sclerosis (ALS).
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: treatedBy Context triple: [spinal muscular atrophy, treatedBy, nusinersen]
-
A.
treatment
chosen
Indicates that one entity is used as a medical or therapeutic intervention to address, manage, or cure a condition affecting another entity.
-
B.
triedBy
Indicates that an entity has made an attempt to perform an action on, or in relation to, another entity.
-
C.
treats
Indicates that one entity provides medical care or therapeutic intervention to another entity.
-
D.
attendedBy
Indicates that an event, place, or activity is participated in or visited by a particular person or group.
-
E.
treatmentLocation
Indicates the place or facility where a treatment or medical intervention is administered to an entity.
- F. None of above.
Provenance (4 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69a494082a7c819095004f423f294a64 |
completed | March 1, 2026, 7:31 p.m. |
| NER | Named-entity recognition | batch_69a4bce821b481908bc278a3fa7973f4 |
completed | March 1, 2026, 10:25 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69ac7f323bbc8190a55fe2101f9561e2 |
completed | March 7, 2026, 7:40 p.m. |
| PD | Predicate disambiguation | batch_69a4bb5656948190b0b1d5446ad06005 |
completed | March 1, 2026, 10:19 p.m. |
Created at: March 1, 2026, 7:45 p.m.